Schoen Klinik Group, Germany’s fourth-largest family-run hospital, is exiting the UK market, following a portfolio reconsideration. With this exit, Schoen Klinik will now focus primarily on its core market, Germany.
Ahead of the HBI 2026 session ‘The new global pharma order: Trump, China and Europe's uncertain future’, HBI spoke to Stephen Farrelly, Managing Director, Global Lead Healthcare & Pharma at ING and Diederik Stadig, Senior Economist, Healthcare & Pharma at ING on what the future holds for pharma investment and strategy, from regulatory risks and European biopharma's structural challenges to the evolving role of CDMOs, CROs, and the role of private equity.
HBI spoke with Viren Shetty, Executive Vice Chairman at Narayana Health, about the rationale behind the deal, the group’s strategy for the UK, and how it approaches international expansion and healthcare investment across markets including India and the UK.
Proximie is a UK-headquartered healthtech company that has built a platform aimed at improving the way surgery is done and the way operating rooms (ORs) function. In the first few years of the company’s existence, it was essentially a telehealth platform for surgeons, helping them collaborate, guide and educate one another across the world via a video connection. But since HBI last interviewed Proximie's CEO and founder Nadine Hachach-Haram in 2023, it’s been transformed into a super-high-tech platform that uses ambient data capture and AI to optimise OR workflows and improve surgery outcomes.
By 2030, some forecasters see the healthcare landscape transforming from a reactive, acute-care model into a proactive, personalised, and data-driven ecosystem. This shift will be underpinned by the integration of advanced technologies like genomics, the Internet of Medical Things and of course AI. In this vision, healthcare will be reshaped by precision medicine, decentralised care, intelligent hospitals, and AI enabled diagnostics.
Private equity firm Lone Star Funds has acquired the Capsules & Health Ingredients (CHI) division of Swiss Contract Development and Manufacturing Organisation (CDMO) Lonza Group for an enterprise value of CHF 2.3 billion (~$3 billion). Headquartered in Basel, Switzerland, the CHI business manufactures capsules used to deliver medicines and dietary supplements. It operates across the Americas, Europe, and the Asia Pacific.
HBI caught up with Sharon Lamb, partner at global law firm McDermott Will & Schulte, about the current investment climate, the impact of government policy on private providers, and where capital is likely to flow next.
Ahead of the Ophthalmology Community Summit at HBI 2026 in partnership with Carl Zeiss Meditec, HBI speaks to Ana Neves, Head of Global Strategic Marketing, and Michael Achtelik, Managing Director of Carl Zeiss Meditec about how digital workflows, interoperability and AI are influencing the development of ophthalmic care, and what Europe may be able to learn from developments in Asia, and vice versa.
Private equity firm Verdane has sold Scandinavian tech company Omilon to private equity firm TA Associates backed-German health technology company, Nexus AG. Omilon provides AI-powered, speech-recognition, and voice-driven clinical documentation software.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
